Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development

[1]  R. Diaz-Arrastia,et al.  Emergency Department Evaluation of Traumatic Brain Injury in the United States, 2009–2010 , 2016, The Journal of head trauma rehabilitation.

[2]  N. Race,et al.  Structural and biochemical abnormalities in the absence of acute deficits in mild primary blast-induced head trauma. , 2016, Journal of neurosurgery.

[3]  P. Bergold.  Treatment of traumatic brain injury with anti-inflammatory drugs , 2016, Experimental Neurology.

[4]  David Tweedie,et al.  Blast traumatic brain injury–induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4 , 2016, Alzheimer's & Dementia.

[5]  N. Greig,et al.  Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice , 2015, Journal of neurochemistry.

[6]  Xiao-hui Wang,et al.  Exendin-4 antagonizes Aβ1-42-induced suppression of long-term potentiation by regulating intracellular calcium homeostasis in rat hippocampal neurons , 2015, Brain Research.

[7]  N. Greig,et al.  What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general? , 2015, The lancet. Psychiatry.

[8]  Ann C. McKee,et al.  Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy , 2015, Nature.

[9]  D. Tweedie,et al.  Post-trauma administration of the pifithrin-α oxygen analog improves histological and functional outcomes after experimental traumatic brain injury , 2015, Experimental Neurology.

[10]  D. Liebeskind,et al.  Targeted Lipid Profiling Discovers Plasma Biomarkers of Acute Brain Injury , 2015, PloS one.

[11]  M. Chopp,et al.  Investigational agents for treatment of traumatic brain injury , 2015, Expert opinion on investigational drugs.

[12]  A. McKee,et al.  Post-traumatic neurodegeneration and chronic traumatic encephalopathy , 2015, Molecular and Cellular Neuroscience.

[13]  Jian-Yi Guo,et al.  Proteomics analysis after traumatic brain injury in rats: the search for potential biomarkers. , 2015, Arquivos de neuro-psiquiatria.

[14]  N. Greig,et al.  Transiently lowering tumor necrosis factor-α synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice , 2015, Journal of Neuroinflammation.

[15]  Tzong-Shiue Yu,et al.  Donepezil Rescues Spatial Learning and Memory Deficits following Traumatic Brain Injury Independent of Its Effects on Neurogenesis , 2015, PloS one.

[16]  Gang Yuan,et al.  Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Reduces Alzheimer Disease-Associated Tau Hyperphosphorylation in the Hippocampus of Rats With Type 2 Diabetes , 2015, Journal of Investigative Medicine.

[17]  S. Parvez,et al.  Role of Melatonin in Traumatic Brain Injury and Spinal Cord Injury , 2014, TheScientificWorldJournal.

[18]  A. Tuttolomondo,et al.  Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date , 2014, Drug design, development and therapy.

[19]  J. Sahuquillo,et al.  Validation of a prognostic score for early mortality in severe head injury cases. , 2014, Journal of neurosurgery.

[20]  L. Alberghina,et al.  Astrocyte–neuron interplay in maladaptive plasticity , 2014, Neuroscience & Biobehavioral Reviews.

[21]  C. Hölscher.  Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. , 2014, Biochemical Society transactions.

[22]  N. Greig,et al.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury , 2014, Alzheimer's & Dementia.

[23]  L. Ferrucci,et al.  A new roadmap for drug development for Alzheimer's disease , 2013, Nature Reviews Drug Discovery.

[24]  N. Greig,et al.  Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats , 2013, PloS one.

[25]  N. Greig,et al.  Cognitive Impairments Accompanying Rodent Mild Traumatic Brain Injury Involve p53-Dependent Neuronal Cell Death and Are Ameliorated by the Tetrahydrobenzothiazole PFT-α , 2013, PloS one.

[26]  N. Greig,et al.  Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice , 2013, AGE.

[27]  S. Cuzzocrea,et al.  Traumatic brain injury: oxidative stress and neuroprotection. , 2013, Antioxidants & redox signaling.

[28]  N. Greig,et al.  Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury , 2013, Neurobiology of Disease.

[29]  C. Bondi,et al.  Donepezil is ineffective in promoting motor and cognitive benefits after controlled cortical impact injury in male rats. , 2013, Journal of neurotrauma.

[30]  N. Greig,et al.  Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice , 2013, Experimental Neurology.

[31]  J. Long,et al.  Acute Minocycline Treatment Mitigates the Symptoms of Mild Blast-Induced Traumatic Brain Injury , 2012, Front. Neur..

[32]  N. Greig,et al.  Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders , 2012, British journal of pharmacology.

[33]  L. Nicholson,et al.  Proline Isomer-Specific Antibodies Reveal the Early Pathogenic Tau Conformation in Alzheimer's Disease , 2012, Cell.

[34]  Shruti V. Kabadi,et al.  Selective CDK Inhibitor Limits Neuroinflammation and Progressive Neurodegeneration after Brain Trauma , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  Frederico A. C. Azevedo,et al.  How many neurons do you have? Some dogmas of quantitative neuroscience under revision , 2012, The European journal of neuroscience.

[36]  N. Marklund,et al.  Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here? , 2011, British journal of pharmacology.

[37]  N. Greig,et al.  Tumor necrosis factor‐α synthesis inhibitor, 3,6′‐dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice , 2011, Journal of neurochemistry.

[38]  K. Yaffe,et al.  Traumatic brain injury and risk of dementia in older veterans , 2011, Alzheimer's & Dementia.

[39]  K. Katki,et al.  Early TBI-Induced Cytokine Alterations are Similarly Detected by Two Distinct Methods of Multiplex Assay , 2011, Front. Mol. Neurosci..

[40]  S. Schreiber,et al.  The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI) , 2011, Psychopharmacology.

[41]  N. Greig,et al.  Lost in Translation: Neuropsychiatric Drug Development , 2010, Science Translational Medicine.

[42]  Harvey B. Pollard,et al.  Reverse phase protein microarray technology in traumatic brain injury , 2010, Journal of Neuroscience Methods.

[43]  M. Wald,et al.  Traumatic brain injury in the United States; emergency department visits, hospitalizations, and deaths, 2002-2006 , 2010 .

[44]  Luis Serrano,et al.  Correlation of mRNA and protein in complex biological samples , 2009, FEBS letters.

[45]  Eileen Maloney,et al.  A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. , 2009, Journal of neurotrauma.

[46]  N G Harris,et al.  Traumatic brain injury results in disparate regions of chondroitin sulfate proteoglycan expression that are temporally limited , 2009, Journal of neuroscience research.

[47]  F. Pontén,et al.  Correlations between RNA and protein expression profiles in 23 human cell lines , 2009, BMC Genomics.

[48]  B. Hoffer,et al.  Closed head injury in a mouse model results in molecular changes indicating inflammatory responses. , 2009, Journal of neurotrauma.

[49]  Frederico A. C. Azevedo,et al.  Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled‐up primate brain , 2009, The Journal of comparative neurology.

[50]  B. Zink,et al.  Pathophysiology of traumatic brain injury. , 2009, The Mount Sinai journal of medicine, New York.

[51]  M. Mattson,et al.  GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism , 2009, Proceedings of the National Academy of Sciences.

[52]  K. Kullander,et al.  Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury. , 2008, Journal of neurotrauma.

[53]  R. Bullock,et al.  Moderate and severe traumatic brain injury in adults , 2008, The Lancet Neurology.

[54]  M. Fujiki,et al.  Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury , 2008, Journal of Clinical Neuroscience.

[55]  J. Ballesteros,et al.  The Effectiveness of Donepezil for Cognitive Rehabilitation After Traumatic Brain Injury: A Systematic Review , 2008, The Journal of head trauma rehabilitation.

[56]  S. Wisniewski,et al.  Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: effects of moderate hypothermia. , 2007, Journal of neurotrauma.

[57]  C. Werner,et al.  Pathophysiology of traumatic brain injury. , 2007, British journal of anaesthesia.

[58]  N. Greig,et al.  Apoptotic and behavioral sequelae of mild brain trauma in mice , 2007, Journal of neuroscience research.

[59]  S. Schreiber,et al.  Apoptotic changes in the cortex and hippocampus following minimal brain trauma in mice , 2007, Brain Research.

[60]  R. Weizman,et al.  Mild traumatic brain injury induces persistent cognitive deficits and behavioral disturbances in mice. , 2005, Journal of neurotrauma.

[61]  Seon-Young Kim,et al.  PAGE: Parametric Analysis of Gene Set Enrichment , 2005, BMC Bioinform..

[62]  T. Kırış,et al.  The effects of memantine on lipid peroxidation following closed-head trauma in rats , 2005, Neurosurgical Review.

[63]  J. P. Schwartz,et al.  Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice , 2003, Neuroscience.

[64]  M. Mattson,et al.  Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron , 2003 .

[65]  M. Mattson,et al.  Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4 , 2002, Journal of Pharmacology and Experimental Therapeutics.

[66]  R. Dempsey,et al.  Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats , 2001, Brain Research.

[67]  M. Bayley,et al.  Open-label study of donepezil in traumatic brain injury. , 2001, Archives of physical medicine and rehabilitation.

[68]  C. Ikonomidou,et al.  Neuronal death enhanced by N-methyl-D-aspartate antagonists. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[69]  S. Schultz,et al.  Donepezil in the Treatment of Cognitive Dysfunction Associated with Traumatic Brain Injury , 2000, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[70]  A. Kriegstein,et al.  Glutamate neurotoxicity in cortical cell culture , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[71]  N. Sen,et al.  Traumatic brain injury: a risk factor for neurodegenerative diseases , 2016, Reviews in the neurosciences.

[72]  E. Sribnick,et al.  Recent developments in clinical trials for the treatment of traumatic brain injury. , 2015, Handbook of clinical neurology.

[73]  B. Stoica,et al.  Cell death mechanisms and modulation in traumatic brain injury , 2011, Neurotherapeutics.

[74]  D. Hovda,et al.  The molecular pathophysiology of concussive brain injury. , 2011, Clinics in sports medicine.

[75]  M. Mattson,et al.  GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[76]  S. Schreiber,et al.  Minimal Traumatic Brain Injury Induce Apoptotic Cell Death in Mice , 2008, Journal of Molecular Neuroscience.

[77]  M. Mattson,et al.  Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. , 2003, Journal of neuroscience research.

[78]  S. Lichtman,et al.  Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. , 1998, Brain injury.